Asymmetrical dose-responses shape the evolutionary trade-off between antifungal resistance and nutrient use
P. C. Despres, A. F. Cisneros Caballero, E. M. Alexander, R. Sonigara, C. Gagne-Thivierge, A. K. Dube, C. R. Landry
Abstract
Antimicrobial resistance is an emerging threat for public health. The success of resistance mutations depends on the trade-off between the benefits and costs they incur. This trade-off is largely unknown and uncharacterized for antifungals. Here, we systematically measure the effect of all amino acid substitutions in the yeast cytosine deaminase Fcy1, the target of the antifungal 5-FC (flucytosine). We identify over 900 missense mutations granting resistance to 5-FC, a large fraction of which appear to act through destabilisation of the protein. The relationship between 5-FC resistance and growth sustained by cytosine deamination is characterized by a sharp trade-off, such that small gains in resistance universally lead to large losses in canonical enzyme function. We show that this steep relationship can be explained by differences in the dose-response functions of 5-FC and cytosine. Finally, we observe the same trade-off shape for the ortholog of FCY1 in Cryptoccocus neoformans, a human pathogen. Our results provide a powerful resource and platform for interpreting drug target variants in fungal pathogens as well as unprecedented insights into resistance-function trade-offs.
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Cross-feeding affects the target of resistance evolution to an antifungal drug
Romain Durand, Jordan Jalbert-Ross, … Christian R. Landry·PLoS GeneticsPeer-reviewed·Oct 19, 2023
- Hypermutation in Cryptococcus reveals anovel pathway to 5-fluorocytosine (5FC) resistance
R. B. Billmyre, S. Applen Clancey, … J. Heitman·bioRxiv·Oct 10, 2019
- Epistasis limits but does not prevent the transfer of mutation-drug resistance mapping across 600 million years of fungal evolution
Marie-Ève Picard, Romain Durand, … Christian R. Landry·bioRxiv·Jul 8, 2026
- Most azole antifungal resistance mutations in the drug target provide cross-resistance and carry no intrinsic fitness cost
Camille Bédard, Isabelle Gagnon‐Arsenault, … Christian R. Landry·Nature MicrobiologyPeer-reviewed·Oct 8, 2024
- tRNA hypomodification facilitates 5-fluorocytosine resistance via cross-pathway control system activation in Aspergillus fumigatus.
Alexander Bruch, Valentina Lazarova, … Matthew G. Blango·Nucleic Acids ResearchPeer-reviewed·Dec 23, 2024
- Distinct binding modes shape exploitable asymmetries between echinocandin and triterpenoid resistance landscapes in Fks1
Hans Carolus, Nagene Wang, … Christian R. Landry·bioRxiv·Nov 11, 2026